MoonLake Immunotherapeutics (MLTX) — Strategic Asset Allocation Index
MoonLake Immunotherapeutics (MLTX) has a Strategic Asset Allocation Index of 0.0% as of June 2023. Strategic assets (PP&E of $42.81K plus long-term investments of $-) total $42.81K, measured against net assets of $499.11 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
MoonLake Immunotherapeutics Strategic Asset Allocation Index (2022–2022)
This chart shows how MoonLake Immunotherapeutics's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2023, the index stands at 0.0%, representing strategic assets of $42.81K against net assets of $499.11 Million USD. Explore MLTX cash generation efficiency to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for MoonLake Immunotherapeutics (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for MoonLake Immunotherapeutics from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see MLTX company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.1% | $49.39K | $49.39K | $- | $68.77 Million | — |